Vertex Pharmaceuticals.
American pharmaceutical company
- Reports this week
- 3
- Active events
- 3
- Connections
- 183
What's happening
Active this week
-
Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.Some support2 reports
-
NIH funded pivotal research for drug development involving Vertex Pharmaceuticals.Some support2 reports
Earlier this month
One to three months ago
-
Vertex Pharmaceuticals CEO leads the company's strategic business direction.Some support1 report
-
Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.Some support2 reports
-
Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.Some support1 report
-
Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.Some support1 report
-
Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.Some support1 report
-
Vertex Pharmaceuticals trades on Nasdaq, files reports with the SEC, and has an executive named Duncan McKechnie.Some support1 report
-
Direct financial comparison of two market rivals: Vertex Pharmaceuticals and Prothena Corporation plc.Some support1 report
-
AbbVie previously failed challenges against Vertex Pharmaceuticals in the context of Cystic Fibrosis (CF).Some support1 report
-
Norges Bank acquired a new position in the shares of Vertex Pharmaceuticals.Some support2 reports
-
Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.Some support1 report
-
Vertex Pharmaceuticals lost market share due to illegal knockoffs of its medicines.Some support2 reports1 development inside
-
Siona's trial failure allowed Vertex dominance to surge.Some support2 reports
-
FogPharma and Vertex Pharmaceuticals are involved in drug development.Some support1 report
-
Vertex Pharmaceuticals filed documents with the SEC detailing institutional investment oversight.Some support1 report
-
Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.Some support2 reports
-
Ono Pharmaceutical and Vertex Pharmaceuticals signed an exclusive collaboration for Povetacicept in Japan and South Korea.Some support3 reports
-
Vertex Pharmaceuticals and Truist Financial disclosed insider trading transactions to the SEC.Some support5 reports
-
MarketBeat listed Vertex, Alnylam, Regeneron, Amgen, Danaher, TG Therapeutics, and Gilead Sciences as stocks to watch.Some support4 reports
-
Vertex Pharmaceuticals and Entera Bio were compared based on their market metrics.Some support1 report
-
Leerink Partners advised Crinetics during the acquisition process, while analyst commentary scrutinized the acquisition premium.Some support1 report
Gone quiet
No new reports in 90+ days-
Various ETFs, including Invesco and VanEck, are reported to hold significant positions in major biotech and pharmaceutical companies.Some support5 reports1 development inside
-
Moderna and Vertex Pharmaceuticals are now holdings in the GNOM ETF.Some support1 report
-
Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.Well supported10 reports
-
The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.Well supported9 reports
-
Market activity on July 7, 2026 includes Deutsche Bank upgrading First Solar stock, the acquisition of Crinetics by Vertex Pharmaceuticals, and market selloffs affecting chip stocks and Korea.Some support2 reports
-
Vertex Pharmaceuticals stock gains far exceeded S&P 500 returns on July 6, 2026.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.Well supported18 reports
-
MarketBeat featured Danaher, Moderna, and Vertex Pharmaceuticals in its stock screener.Some support23 reports
-
Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick on July 15, 2025.Some support3 reports1 development inside
-
Vertex Pharmaceuticals stock price objective was boosted, triggering a requirement for 13F filings regarding stock ownership.Some support1 report1 development inside
-
Carmen Bozic, CMO of Vertex Pharmaceuticals, sold company stock on June 23, 2026.Some support1 report
-
CRISPR and Vertex Pharmaceuticals developed the CASGEVY therapy, noting growing treatment centers in Europe and the US.Some support1 report
-
Benzinga reported on the financial performance of Vertex Pharmaceuticals.Some support1 report
-
Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.Some support1 report
-
The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.Some support1 report
-
EPAM Systems, Paramount Global, and Vertex Pharmaceuticals were identified as major high-growth stocks.Speculative1 report
-
Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.Some support1 report
-
Vertex Pharmaceuticals presented clinical data at the American Diabetes Association conference held in Chicago on June 25, 2025.Speculative2 reports
-
PGIM Jennison Health Sciences Fund held Vertex Pharmaceuticals in its portfolio in July 2025.Speculative2 reports
-
Vertex Pharmaceuticals' performance is linked to broader market movements, supported by new reimbursement agreements in Ireland and Denmark.Speculative2 reports
-
A reimbursement deal for the drug ALYFTREK has been reached between Vertex Pharmaceuticals and NHS England.Well supported4 reports
-
Vertex Pharmaceuticals and Inspire Medical Systems both reported positive Earnings Stock Purchase Plan (ESP) figures.Some support1 report
-
Vertex Pharmaceuticals, based in Boston, launched JOURNAVX, a new medication offering a safer alternative to opioids.Some support1 report
-
FDA approved Journavx for pain treatment on August 1, 2025.Some support2 reports
-
Vertex Pharmaceuticals was removed from Russell indexes on August 7, 2025.Some support1 report
-
Buying opportunities emerged for Costco, Netflix, ASML Holding, and Vertex Pharmaceuticals following a market pullback on August 8, 2025.Some support1 report1 development inside
-
The Buffett Indicator reached a record high, involving Vertex Pharmaceuticals.Some support1 report
-
FDA feedback limited the initial scope of suzetrigine, leading to Goldman Sachs analysts questioning the drug's label loss.Some support2 reports
-
Vertex Pharmaceuticals and Netflix were highlighted as attractive investment options on August 15, 2025.Some support1 report
-
CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.Well supported6 reports1 development inside
-
Vertex Pharmaceuticals is based in Boston, Massachusetts.Well supported7 reports
-
Vertex Pharmaceuticals and Maze Therapeutics are developing treatments for APOL1-Mediated Kidney Disease, leading to regulatory scrutiny.Some support2 reports
-
Pfizer and Vertex Pharmaceuticals were featured as high-growth pharmaceutical stocks.Some support2 reports
-
Vertex Pharmaceuticals and Enlaza Therapeutics formed a strategic collaboration to develop new drug conjugates using Enlaza's War-Lock platform.Some support1 report
-
ClearBridge All Cap Growth Strategy highlighted Vertex Pharmaceuticals on September 3, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Vertex Pharmaceuticals
Events traced to Vertex Pharmaceuticals, step by step, newest firstAround Vertex Pharmaceuticals this week
News at the entities that move Vertex Pharmaceuticals most-
CRISPR Therapeutics StructuralCRISPR Therapeutics announced that A.J. Silver will succeed Raju Prasad as CFO, following Silver's time at Ernst & Young LLP.Moves Vertex Pharmaceuticals
-
FDA StructuralCongress and the Senate are considering legislation affecting FDA submissions and drug patent rights.Moves Vertex Pharmaceuticals
-
Bank of America TransactionalFinancial institutions including Barclays, Morgan Stanley, and Bank of America provided analyst coverage and target price reports for Sonic Automotive on May 27, 2026.Moves Vertex Pharmaceuticals
-
Royal Bank of Canada OperationalRoyal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.Moves Vertex Pharmaceuticals
-
Securities and Exchange Commission StructuralNewLake Capital Partners, Inc. filed Form 13F with the Securities and Exchange Commission.Moves Vertex Pharmaceuticals
-
Morgan Stanley TransactionalMultiple financial institutions issued price target and rating updates for CAE Inc. on October 1, 2026.Moves Vertex Pharmaceuticals
Connections
The 40 strongest of 183, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
CRISPR Therapeutics Structural
CRISPR and Vertex maintain a strategic partnership for the joint development, commercialization, and shared profitability of the gene therapy Casgevy.
-
Crinetics Pharmaceuticals Structural
Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals in a $10 billion deal, establishing a parent-subsidiary relationship.
-
Reshma Kewalramani Structural
Reshma Kewalramani serves as the CEO and President, leading the strategic direction of Vertex Pharmaceuticals.
-
FDA Structural
FDA formally regulates Vertex Pharmaceuticals through drug approvals, designations, and scope limitations on treatments.
-
Morgan Stanley Transactional
Morgan Stanley provides financial advisory, ratings, and bridge financing services to Vertex Pharmaceuticals.
-
Bank of America Transactional
Bank of America provided analyst coverage and bridge financing for Vertex Pharmaceuticals' acquisition.
-
Duncan McKechnie Structural
Duncan McKechnie serves as an executive, EVP, at Vertex Pharmaceuticals.
-
SPDR Structural
SPDR ETF holds a significant stake in Vertex Pharmaceuticals as part of its managed portfolio.
Show all 40 connections
-
Royal Bank of Canada Operational
RBC provides financial ratings and price target recommendations that influence the market perception and stock performance of Vertex Pharmaceuticals.
-
Securities and Exchange Commission Structural
Vertex Pharmaceuticals is subject to formal regulatory oversight by the SEC, requiring specific stock ownership filings (13F).
-
Moderna Operational
Both companies are active peers in the competitive therapeutics segment, focusing on advanced treatments like AI in Synthetic Biology.
-
SEC Structural
Vertex Pharmaceuticals is subject to SEC oversight regarding institutional holdings and required regulatory filings.
-
Amgen Operational
Vertex and Amgen are direct competitors in the biopharmaceutical market, frequently compared by investors and market analysts.
-
Norges Bank Transactional
Norges Bank acquired a new position in Vertex Pharmaceuticals shares.
-
Invesco Structural
Invesco holds a large financial position in Vertex Pharmaceuticals.
-
Denmark Operational
Vertex Pharmaceuticals gains market access in Denmark through formal reimbursement agreements.
-
Halozyme Therapeutics Structural
The relationship is characterized by a formal partnership structure where one entity operates as a subsidiary regarding Hypercon technology.
-
Cystic Fibrosis Foundation Operational
Vertex Pharmaceuticals develops treatments that actively support the mission and focus area of the Cystic Fibrosis Foundation.
-
TD Cowen Mentioned together
TD Cowen provides financial analysis and rating coverage for Vertex Pharmaceuticals.
-
England Operational
Vertex Pharmaceuticals' medicine is covered by the National Health Service in England via a formal reimbursement agreement.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides investment analysis and target price ratings for Vertex Pharmaceuticals.
-
Leerink partners Mentioned together
Leerink Partners provides market coverage and sets price targets for Vertex Pharmaceuticals shares.
-
National Institutes of Health Transactional
NIH provided funding to Vertex Pharmaceuticals for pivotal research in drug development.
-
Citigroup Operational
Citigroup publicly upgraded its investment recommendation regarding Vertex Pharmaceuticals, influencing market perception.
-
AbbVie Operational
AbbVie and Vertex Pharmaceuticals are engaged in direct market and legal competition.
-
SpaceX Operational
The relationship is characterized by active competition, with Vertex Pharmaceuticals noted to possess greater market dominance than SpaceX.
-
Biogen Operational
Vertex Pharmaceuticals and Biogen are direct competitors, both developing and marketing therapies for serious diseases.
-
RBC Capital Markets Transactional
Analyst commentary focuses on the acquisition premium between the two companies.
-
Goldman Sachs Mentioned together
Goldman Sachs provides financial analysis, stock picks, and buy ratings for Vertex Pharmaceuticals.
-
Biotech Shared context
Vertex Pharmaceuticals is identified as a major holding within the broader biotech sector ETF.
-
FogPharma Mentioned together
The companies are co-mentioned as entities involved in the drug development industry.
-
Danaher Corporation Mentioned together
Both companies are identified as major players within the biotech sector.
-
Benzinga Mentioned together
Benzinga, a financial news service, reports on and disseminates information regarding Vertex Pharmaceuticals' financial performance.
-
Leiden Shared context
Vertex Pharmaceuticals is contextually linked to Leiden via the historical role of a former CEO.
-
Gilead Sciences Operational
Both companies are identified as major competitors operating in the biotechnology sector.
-
Nvidia Mentioned together
The entities are co-mentioned in market analysis as high-growth stocks.
-
MarketBeat Mentioned together
MarketBeat features Vertex Pharmaceuticals in its stock screener and watch lists, providing consensus rating data.
-
Truist Financial Mentioned together
Truist Financial provides market research coverage, including target price boosts and rating changes, for Vertex Pharmaceuticals.
-
Europe Shared context
Vertex Pharmaceuticals conducts clinical trials, gains regulatory approval, and markets products within the European market.
-
Wells Fargo Shared context
Vertex Pharmaceuticals presented updates at a Wells Fargo conference.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
5 events- Both Vertex Pharmaceuticals and The Pennant Group operate within the healthcare sector.
- Vertex Pharmaceuticals CEO leads the company's strategic business direction.
- Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.
- Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.
- Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.
August 2026
11 events- Vertex Pharmaceuticals trades on Nasdaq, files reports with the SEC, and has an executive named Duncan McKechnie.
- Direct financial comparison of two market rivals: Vertex Pharmaceuticals and Prothena Corporation plc.
- AbbVie previously failed challenges against Vertex Pharmaceuticals in the context of Cystic Fibrosis (CF).
- Norges Bank acquired a new position in the shares of Vertex Pharmaceuticals.
- Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.
- Siona's trial failure allowed Vertex dominance to surge.
- FogPharma and Vertex Pharmaceuticals are involved in drug development.
- Vertex Pharmaceuticals filed documents with the SEC detailing institutional investment oversight.
- Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.
- Vertex Pharmaceuticals and Truist Financial disclosed insider trading transactions to the SEC.
- MarketBeat listed Vertex, Alnylam, Regeneron, Amgen, Danaher, TG Therapeutics, and Gilead Sciences as stocks to watch.
Show 2 earlier months
July 2026
8 events- The competitive landscape is shifting as Amazon's Leo challenges Starlink's business, while Vertex Pharmaceuticals demonstrates market dominance over SpaceX.
- Vertex Pharmaceuticals and Entera Bio were compared based on their market metrics.
- Leerink Partners advised Crinetics during the acquisition process, while analyst commentary scrutinized the acquisition premium.
- Various ETFs, including Invesco and VanEck, are reported to hold significant positions in major biotech and pharmaceutical companies.
- Moderna and Vertex Pharmaceuticals are now holdings in the GNOM ETF.
- Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.
- Market activity on July 7, 2026 includes Deutsche Bank upgrading First Solar stock, the acquisition of Crinetics by Vertex Pharmaceuticals, and market selloffs affecting chip stocks and Korea.
- Vertex Pharmaceuticals stock gains far exceeded S&P 500 returns on July 6, 2026.
June 2026
34 events- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
- Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.
- Vertex Pharmaceuticals lost market share due to illegal knockoffs of its medicines.
- Ono Pharmaceutical and Vertex Pharmaceuticals signed an exclusive collaboration for Povetacicept in Japan and South Korea.
- The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
- CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.
- MarketBeat featured Danaher, Moderna, and Vertex Pharmaceuticals in its stock screener.
- Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick on July 15, 2025.
- Vertex Pharmaceuticals stock price objective was boosted, triggering a requirement for 13F filings regarding stock ownership.
- Carmen Bozic, CMO of Vertex Pharmaceuticals, sold company stock on June 23, 2026.
- CRISPR and Vertex Pharmaceuticals developed the CASGEVY therapy, noting growing treatment centers in Europe and the US.
- Benzinga reported on the financial performance of Vertex Pharmaceuticals.
- Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.
- The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.
- EPAM Systems, Paramount Global, and Vertex Pharmaceuticals were identified as major high-growth stocks.
- Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.
- Vertex Pharmaceuticals presented clinical data at the American Diabetes Association conference held in Chicago on June 25, 2025.
- PGIM Jennison Health Sciences Fund held Vertex Pharmaceuticals in its portfolio in July 2025.
- Vertex Pharmaceuticals' performance is linked to broader market movements, supported by new reimbursement agreements in Ireland and Denmark.
- A reimbursement deal for the drug ALYFTREK has been reached between Vertex Pharmaceuticals and NHS England.
- Vertex Pharmaceuticals and Inspire Medical Systems both reported positive Earnings Stock Purchase Plan (ESP) figures.
- Vertex Pharmaceuticals, based in Boston, launched JOURNAVX, a new medication offering a safer alternative to opioids.
- FDA approved Journavx for pain treatment on August 1, 2025.
- Vertex Pharmaceuticals was removed from Russell indexes on August 7, 2025.
- Buying opportunities emerged for Costco, Netflix, ASML Holding, and Vertex Pharmaceuticals following a market pullback on August 8, 2025.
- The Buffett Indicator reached a record high, involving Vertex Pharmaceuticals.
- FDA feedback limited the initial scope of suzetrigine, leading to Goldman Sachs analysts questioning the drug's label loss.
- Vertex Pharmaceuticals and Netflix were highlighted as attractive investment options on August 15, 2025.
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
- Vertex Pharmaceuticals is based in Boston, Massachusetts.
- Vertex Pharmaceuticals and Maze Therapeutics are developing treatments for APOL1-Mediated Kidney Disease, leading to regulatory scrutiny.
- Pfizer and Vertex Pharmaceuticals were featured as high-growth pharmaceutical stocks.
- Vertex Pharmaceuticals and Enlaza Therapeutics formed a strategic collaboration to develop new drug conjugates using Enlaza's War-Lock platform.
- ClearBridge All Cap Growth Strategy highlighted Vertex Pharmaceuticals on September 3, 2025.